One participant with ERBB2-mutant breast cancer who was recommended for clinical trials was started on treatment with neratinib on compassionate basis - this was overall judged to be consistent with following the two GTAB recommendations to consider clinical trials for access to ERRB2-directed therapy for this participant. The gene discussed is ESRRB; the disease is breast cancer.